CompletedNCT00206544
Tamoxifen or progesterone added for acute mania in women with bipolarity
About this title
Read the official source — NCT00206544Medication studyAges 18–50Australia
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- MelbourneSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- The Alfred
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Australia
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00206544
- Official title
Show the full official title
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedMelbourne
Questions about this study
Who is behind this study?
The study sponsor is The Alfred.
Did this study involve medication?
Yes. The study involved medication, including Tamoxifen and Progesterone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Estradiol or placebo for psychosis symptoms in women with schizophrenia
A placebo and comparator controlled phase 1, safety and tolerability study of 3 ascending doses of INP105 (intranasal OLZ by I231 POD® device).